The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
Titel:
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
Auteur:
Saturno, G. Lopes, F. Niculescu-Duvaz, I. Niculescu-Duvaz, D. Zambon, A. Davies, L. Johnson, L. Preece, N. Lee, R. Viros, A. Holovanchuk, D. Pedersen, M. McLeary, R. Lorigan, P. Dhomen, N. Fisher, C. Banerji, U. Dean, E. Krebs, M.G. Gore, M. Larkin, J. Marais, R. Springer, C.